These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 37545232)

  • 1. Serum Neurofilament Light Chain in the Diagnostic Evaluation of Patients with Cognitive Symptoms in the Neurological Consultation of a Tertiary Center.
    Lopes das Neves P; Durães J; Silva-Spinola A; Lima M; Leitão MJ; Tábuas-Pereira M; Santana I; Baldeiras I
    J Alzheimers Dis; 2023; 95(2):391-397. PubMed ID: 37545232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Cerebrospinal Fluid Neurofilament Light Protein Levels With Cognition in Patients With Dementia, Motor Neuron Disease, and Movement Disorders.
    Olsson B; Portelius E; Cullen NC; Sandelius Å; Zetterberg H; Andreasson U; Höglund K; Irwin DJ; Grossman M; Weintraub D; Chen-Plotkin A; Wolk D; McCluskey L; Elman L; Shaw LM; Toledo JB; McBride J; Hernandez-Con P; Lee VM; Trojanowski JQ; Blennow K
    JAMA Neurol; 2019 Mar; 76(3):318-325. PubMed ID: 30508027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Combination of Neurofilament Light, Glial Fibrillary Acidic Protein, and Neuronal Pentraxin-2 Discriminates Between Frontotemporal Dementia and Other Dementias.
    Bolsewig K; Hok-A-Hin YS; Sepe FN; Boonkamp L; Jacobs D; Bellomo G; Paoletti FP; Vanmechelen E; Teunissen CE; Parnetti L; Willemse EAJ
    J Alzheimers Dis; 2022; 90(1):363-380. PubMed ID: 36120776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimer's disease.
    Gangishetti U; Christina Howell J; Perrin RJ; Louneva N; Watts KD; Kollhoff A; Grossman M; Wolk DA; Shaw LM; Morris JC; Trojanowski JQ; Fagan AM; Arnold SE; Hu WT
    Alzheimers Res Ther; 2018 Sep; 10(1):98. PubMed ID: 30253800
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alzheimer's disease biomarker-guided diagnostic workflow using the added value of six combined cerebrospinal fluid candidates: Aβ
    Hampel H; Toschi N; Baldacci F; Zetterberg H; Blennow K; Kilimann I; Teipel SJ; Cavedo E; Melo Dos Santos A; Epelbaum S; Lamari F; Genthon R; Dubois B; Floris R; Garaci F; Lista S;
    Alzheimers Dement; 2018 Apr; 14(4):492-501. PubMed ID: 29328927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease.
    Mattsson N; Cullen NC; Andreasson U; Zetterberg H; Blennow K
    JAMA Neurol; 2019 Jul; 76(7):791-799. PubMed ID: 31009028
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma neurofilament light chain in memory clinic practice: Evidence from a real-life study.
    Götze K; Vrillon A; Bouaziz-Amar E; Mouton-Liger F; Hugon J; Martinet M; Dumurgier J; Cognat E; Zetterberg H; Blennow K; Hourrègue C; Paquet C; Lilamand M
    Neurobiol Dis; 2023 Jan; 176():105937. PubMed ID: 36462720
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic accuracy of CSF neurofilament light chain protein in the biomarker-guided classification system for Alzheimer's disease.
    Lista S; Toschi N; Baldacci F; Zetterberg H; Blennow K; Kilimann I; Teipel SJ; Cavedo E; Dos Santos AM; Epelbaum S; Lamari F; Dubois B; Floris R; Garaci F; Hampel H;
    Neurochem Int; 2017 Sep; 108():355-360. PubMed ID: 28527630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cerebrospinal fluid biomarkers of neurodegeneration, synaptic integrity, and astroglial activation across the clinical Alzheimer's disease spectrum.
    Bos I; Vos S; Verhey F; Scheltens P; Teunissen C; Engelborghs S; Sleegers K; Frisoni G; Blin O; Richardson JC; Bordet R; Tsolaki M; Popp J; Peyratout G; Martinez-Lage P; Tainta M; Lleó A; Johannsen P; Freund-Levi Y; Frölich L; Vandenberghe R; Westwood S; Dobricic V; Barkhof F; Legido-Quigley C; Bertram L; Lovestone S; Streffer J; Andreasson U; Blennow K; Zetterberg H; Visser PJ
    Alzheimers Dement; 2019 May; 15(5):644-654. PubMed ID: 30853464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FDG-PET and CSF biomarker accuracy in prediction of conversion to different dementias in a large multicentre MCI cohort.
    Caminiti SP; Ballarini T; Sala A; Cerami C; Presotto L; Santangelo R; Fallanca F; Vanoli EG; Gianolli L; Iannaccone S; Magnani G; Perani D;
    Neuroimage Clin; 2018; 18():167-177. PubMed ID: 29387532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neurofilament light as a biomarker of axonal degeneration in patients with mild cognitive impairment and Alzheimer's disease.
    Chen Y; Therriault J; Luo J; Ba M; Zhang H; Initiative ADN
    J Integr Neurosci; 2021 Dec; 20(4):861-870. PubMed ID: 34997710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma and CSF biomarkers for the diagnosis of Alzheimer's disease in adults with Down syndrome: a cross-sectional study.
    Fortea J; Carmona-Iragui M; Benejam B; Fernández S; Videla L; Barroeta I; Alcolea D; Pegueroles J; Muñoz L; Belbin O; de Leon MJ; Maceski AM; Hirtz C; Clarimón J; Videla S; Delaby C; Lehmann S; Blesa R; Lleó A
    Lancet Neurol; 2018 Oct; 17(10):860-869. PubMed ID: 30172624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study.
    Lleó A; Alcolea D; Martínez-Lage P; Scheltens P; Parnetti L; Poirier J; Simonsen AH; Verbeek MM; Rosa-Neto P; Slot RER; Tainta M; Izaguirre A; Reijs BLR; Farotti L; Tsolaki M; Vandenbergue R; Freund-Levi Y; Verhey FRJ; Clarimón J; Fortea J; Frolich L; Santana I; Molinuevo JL; Lehmann S; Visser PJ; Teunissen CE; Zetterberg H; Blennow K
    Alzheimers Dement; 2019 Jun; 15(6):742-753. PubMed ID: 30967340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decreased cerebrospinal fluid neuronal pentraxin receptor is associated with PET-Aβ load and cerebrospinal fluid Aβ in a pilot study of Alzheimer's disease.
    Lim B; Fowler C; Li QX; Rowe C; Dhiman K; Gupta VB; Masters CL; Doecke JD; Martins RN; Collins S; Diamandis EP
    Neurosci Lett; 2020 Jul; 731():135078. PubMed ID: 32450185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cerebrospinal fluid in the differential diagnosis of Alzheimer's disease: clinical utility of an extended panel of biomarkers in a specialist cognitive clinic.
    Paterson RW; Slattery CF; Poole T; Nicholas JM; Magdalinou NK; Toombs J; Chapman MD; Lunn MP; Heslegrave AJ; Foiani MS; Weston PSJ; Keshavan A; Rohrer JD; Rossor MN; Warren JD; Mummery CJ; Blennow K; Fox NC; Zetterberg H; Schott JM
    Alzheimers Res Ther; 2018 Mar; 10(1):32. PubMed ID: 29558979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cerebrospinal Fluid Biomarkers in Patients with Frontotemporal Dementia Spectrum: A Single-Center Study.
    Abu-Rumeileh S; Mometto N; Bartoletti-Stella A; Polischi B; Oppi F; Poda R; Stanzani-Maserati M; Cortelli P; Liguori R; Capellari S; Parchi P
    J Alzheimers Dis; 2018; 66(2):551-563. PubMed ID: 30320576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma neurofilament light chain as a biomarker of Alzheimer's disease in Subjective Cognitive Decline and Mild Cognitive Impairment.
    Giacomucci G; Mazzeo S; Bagnoli S; Ingannato A; Leccese D; Berti V; Padiglioni S; Galdo G; Ferrari C; Sorbi S; Bessi V; Nacmias B
    J Neurol; 2022 Aug; 269(8):4270-4280. PubMed ID: 35288777
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cerebrospinal fluid neurofilament light chain differentiates behavioural variant frontotemporal dementia progressors from non-progressors.
    Eratne D; Keem M; Lewis C; Kang M; Walterfang M; Farrand S; Loi S; Kelso W; Cadwallader C; Berkovic SF; Li QX; Masters CL; Collins S; Santillo A; Velakoulis D;
    J Neurol Sci; 2022 Nov; 442():120439. PubMed ID: 36201960
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Testing the 2018 NIA-AA research framework in a retrospective large cohort of patients with cognitive impairment: from biological biomarkers to clinical syndromes.
    Carandini T; Arighi A; Sacchi L; Fumagalli GG; Pietroboni AM; Ghezzi L; Colombi A; Scarioni M; Fenoglio C; De Riz MA; Marotta G; Scarpini E; Galimberti D
    Alzheimers Res Ther; 2019 Oct; 11(1):84. PubMed ID: 31615545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).
    Ritchie C; Smailagic N; Noel-Storr AH; Ukoumunne O; Ladds EC; Martin S
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD010803. PubMed ID: 28328043
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.